Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $50.1 million.

  • Tango Therapeutics' Total Liabilities fell 5934.52% to $50.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year decrease of 5934.52%. This contributed to the annual value of $117.0 million for FY2024, which is 2173.44% down from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Total Liabilities is $50.1 million, which was down 5934.52% from $102.9 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Total Liabilities peaked at $191.1 million during Q3 2022, and registered a low of $6.1 million during Q1 2021.
  • Over the past 5 years, Tango Therapeutics' median Total Liabilities value was $149.5 million (recorded in 2023), while the average stood at $128.0 million.
  • As far as peak fluctuations go, Tango Therapeutics' Total Liabilities skyrocketed by 2534240.87% in 2021, and later plummeted by 5934.52% in 2025.
  • Tango Therapeutics' Total Liabilities (Quarter) stood at $155.4 million in 2021, then increased by 20.32% to $187.0 million in 2022, then fell by 20.07% to $149.5 million in 2023, then fell by 21.73% to $117.0 million in 2024, then plummeted by 57.17% to $50.1 million in 2025.
  • Its Total Liabilities stands at $50.1 million for Q3 2025, versus $102.9 million for Q2 2025 and $107.6 million for Q1 2025.